Literature DB >> 577367

Toxoplasmic chorioretinitis affecting the macula.

M Saari.   

Abstract

To study macular changes in toxoplasmic chorioretinitis 41 patients with ocular toxoplasmosis were reviewed. Of the 41 patients, seven had central, large, deep, pigment ringed scars of congenital toxoplasmosis with poor central vision; squint was seen in two and nystagmus in two; 32, including 11 cases with a macular lesion, had recurrent active toxoplasmic chorioretinitis with a focal, yellowish-white, elevated lesion with indistinct borders mostly at the margin of an old scar and associated with vitreous opacities in all, secondary anterior uveitis in 28, macular oedema in 22, papilloedema in 14, and retinal perivasculitis in 16 cases; two had rare acquired toxoplasmic chorioretinitis affecting the macula. The results show that active toxoplasmic chorioretinitis often causes a widespread intraocular inflammation with vitritis, macular oedema, papilloedema, retinal perivasculitis and secondary anterior uveitis, and suggest a combined treatment of active lesions with antimicrobial agents and corticosteroids.

Entities:  

Mesh:

Year:  1977        PMID: 577367     DOI: 10.1111/j.1755-3768.1977.tb06132.x

Source DB:  PubMed          Journal:  Acta Ophthalmol (Copenh)        ISSN: 0001-639X


  3 in total

1.  Clinical manifestation and prognosis of active ocular toxoplasmosis in Iran.

Authors:  Farzan Kianersi; Afsaneh Naderi Beni; Zahra Naderi Beni
Journal:  Int Ophthalmol       Date:  2012-06-26       Impact factor: 2.031

2.  Demonstration of intraocular synthesis of immunoglobulin G toxoplasma antibodies for specific diagnosis of toxoplasmic chorioretinitis by enzyme immunoassay.

Authors:  H J Turunen; P O Leinikki; K M Saari
Journal:  J Clin Microbiol       Date:  1983-06       Impact factor: 5.948

3.  Visual function in human ocular toxoplasmosis.

Authors:  Janine Scherrer; Milko E Iliev; Markus Halberstadt; Laurent Kodjikian; Justus G Garweg
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.